WE DO NOT SHIP TO RESIDENTIAL ADDRESSES. For pricing in CAD/AUD/NZD please contact us.

Recombinant Human Thymosin Beta 4 (rHuTβ4) - PR1122

Recombinant Human Thymosin Beta 4 (rHuTβ4) - PR1122

Regular price
$260.23
Regular price
Sale price
$260.23
Unit price
per 
Availability
Sold out

Recombinant Human Thymosin Beta 4 (rHuTβ4)

Catalogue Numbers: PR1122-5, PR1122-25

Sizes: 5µg, 25µg

Source: Escherichia coli

Molecular Weight: Approximately 4.9 kDa, a single non-glycosylated polypeptide chain containing 43 amino acids.

Purity: >97% by SDS-PAGE and HPLC analyses.

Biological Activity: Data is not available.

Physical Appearance: Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation: Lyophilized from a 0.2mm filtered concentrated solution in 20mM PB, pH 7.4.

AA Sequence: SDKPDMAEIE KFDKSKLKKT ETQEKNPLPS KETIEQEKQA GES

Endotoxin: Less than 1EU/mg of rHuTβ4 as determined by LAL method.

Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at <-20°C. Further dilutions should be made in appropriate buffered solutions.

Storage: This lyophilized preparation is stable at 2-8°C, but should be kept at -20°C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8°C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to -70°C. Avoid repeated freeze/thaw cycles.

Usage: This material is offered by USA Bioworld biotech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE. Made in China

Description: Thymosin Beta 4 is a naturally occurring peptide. It is found in high concentrations in blood platelets, wound fluid and other tissues in the body. Tβ4 is not a growth factor; rather, it is a major actin regulating peptide. The thymosin beta-4 peptide, if used after a heart attack, might reactivate cardiac progenitor cells to repair damaged heart tissue.